SCHEMBL17457368

SCHEMBL17457368

O=c1[nH]c2ccc(Cl)cc2c(-c2ccncc2)c1-c1ccoc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 15/20 0.61
CDK5 Q00535 1/20 0.49
CDK5R1 Q15078 1/20 0.49
ROCK2 O75116 2/20 0.46
PIM1 P11309 2/20 0.46
MAPK1 P28482 2/20 0.46
GSK3A P49840 2/20 0.46
GSK3B P49841 2/20 0.46
LIMK1 P53667 2/20 0.46
STK3 Q13188 2/20 0.46
CDC42BPA Q5VT25 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MAP4K4 O95819 1/20 0.46
LCK P06239 1/20 0.46
RPS6KB1 P23443 1/20 0.46
CDK2 P24941 1/20 0.46
EPHA2 P29317 1/20 0.46
FLT3 P36888 1/20 0.46
FRK P42685 1/20 0.46
CLK2 P49760 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17457312 0.89 CSF1R (0.70) CSF1RCDK5CDK5R1ROCK2PIM1
SCHEMBL4847486 0.84 CSF1R (0.68) CSF1RROCK2PIM1MAPK1GSK3A
SCHEMBL17457409 0.82 CSF1R (0.60) CSF1RCDK5CDK5R1ROCK2PIM1
SCHEMBL17457377 0.81 CSF1R (0.64) CSF1RCDK5CDK5R1ROCK2PIM1
SCHEMBL17457422 0.80 PADI4 (0.60) CSF1RCDK5CDK5R1ROCK2PIM1
SCHEMBL16111881 0.80 CSF1R (0.59) CSF1RCDK5CDK5R1ROCK2PIM1
SCHEMBL17457413 0.79 CSF1R (0.52) CSF1RFLT3
SCHEMBL31179312 0.77 CSF1R (0.75) CSF1RCDK5CDK5R1ROCK2PIM1
SCHEMBL17457339 0.77 CSF1R (0.59) CSF1RCDK5CDK5R1ROCK2PIM1
SCHEMBL16111646 0.76 CSF1R (0.70) CSF1RCDK5CDK5R1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2968360-B1 QUINOLINONE DERIVATIVES FOR THE INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS CONVERGENE LLC (US) 2021-01-20 EP disclosed
US-10717739-B2 Methods and compositions for inhibition of bromodomain-containing proteins CONVERGENE LLC (US) 2020-07-21 US disclosed
US-10717739-B2 Methods and compositions for inhibition of bromodomain-containing proteins CONVERGENE LLC (US) 2020-07-21 US disclosed
US-20190345162-A1 Methods and Compositions for Inhibition of Bromodomain-Containing Proteins CONVERGENE LLC 2019-11-14 US disclosed
US-20190345162-A1 Methods and Compositions for Inhibition of Bromodomain-Containing Proteins CONVERGENE LLC 2019-11-14 US disclosed
US-10266536-B2 Methods and compositions for inhibition of bromodomain-containing proteins CONVERGENE LLC (US) 2019-04-23 US disclosed
US-10266536-B2 Methods and compositions for inhibition of bromodomain-containing proteins CONVERGENE LLC (US) 2019-04-23 US disclosed
US-20180134715-A1 Methods and Compositions for Inhibition of Bromodomain-Containing Proteins CONVERGENE LLC 2018-05-17 US disclosed
US-20180134715-A1 Methods and Compositions for Inhibition of Bromodomain-Containing Proteins CONVERGENE LLC 2018-05-17 US disclosed
US-20180134715-A1 Methods and Compositions for Inhibition of Bromodomain-Containing Proteins CONVERGENE LLC 2018-05-17 US disclosed
US-9695179-B2 Methods and compositions for inhibition of bromodomain-containing proteins CONVERGENE LLC (US) 2017-07-04 US disclosed
US-9695179-B2 Methods and compositions for inhibition of bromodomain-containing proteins CONVERGENE LLC (US) 2017-07-04 US disclosed
US-9695179-B2 Methods and compositions for inhibition of bromodomain-containing proteins CONVERGENE LLC (US) 2017-07-04 US disclosed
US-20160024096-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS CONVERGENE LLC (US) 2016-01-28 US disclosed
US-20160024096-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS CONVERGENE LLC (US) 2016-01-28 US disclosed
US-20160024096-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS CONVERGENE LLC (US) 2016-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10717739-B2 Methods and compositions for inhibition of bromodomain-containing proteins BRPF3, BRD3, BRDT CSF1R 3174/4885CDK5 72/4885CDK5R1 115/4885
US-20190345162-A1 Methods and Compositions for Inhibition of Bromodomain-Containing Proteins BRPF3, BRD3, BRDT CSF1R 3174/4885CDK5 72/4885CDK5R1 115/4885
US-10266536-B2 Methods and compositions for inhibition of bromodomain-containing proteins BRPF3, BRD3, BRDT CSF1R 3174/4885CDK5 72/4885CDK5R1 115/4885
US-20180134715-A1 Methods and Compositions for Inhibition of Bromodomain-Containing Proteins BRPF3, BRD3, BRDT CSF1R 3174/4885CDK5 72/4885CDK5R1 115/4885
US-20160024096-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, BRD3, BRDT CSF1R 3174/4885CDK5 72/4885CDK5R1 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.